QuickView for CYP1B1;jsessionid=3953E34A356F416CB15FC0085D20B0B2;jsessionid=2637BC8E69C9545D9678EC901E5C385A;jsessionid=39ED254AEEF8BCD459CC34B40364634D;jsessionid=DDD991134760068479A41B92BB59B39B;jsessionid=34E31225B47500CFB2DF25B4D7A00A92;jsessionid=9ED77EF9FD2703252AA89F75F3B39A69;jsessionid=F9ED33B4B73B0E3291B7C0F7B7E18DCE;jsessionid=6708CD85AF36D79EA798E70B7299081B (gene)

1. Variable Phenotype of Congenital Corneal Opacities in Biallelic CYP1B1 Pathogenic Variants.
2. Development of novel N-aryl-2,4-bithiazole-2-amine-based CYP1B1 degraders for reversing drug resista…
3. Lower overall survival in male patients with advanced disease undergoing allogeneic hematopoietic st…
4. 17-(R/S)-hydroxyeicosatetraenoic acid (HETE) induces cardiac hypertrophy through the CYP1B1 in enant…
5. Design of Novel 2-Phenylquinazolin-4-amines as Selective CYP1B1 Inhibitors for Overcoming Paclitaxel…

There were no clinical trials for CYP1B1;jsessionid=3953E34A356F416CB15FC0085D20B0B2;jsessionid=2637BC8E69C9545D9678EC901E5C385A;jsessionid=39ED254AEEF8BCD459CC34B40364634D;jsessionid=DDD991134760068479A41B92BB59B39B;jsessionid=34E31225B47500CFB2DF25B4D7A00A92;jsessionid=9ED77EF9FD2703252AA89F75F3B39A69;jsessionid=F9ED33B4B73B0E3291B7C0F7B7E18DCE;jsessionid=6708CD85AF36D79EA798E70B7299081B